Advancing science and implementing novel, cutting edge Technologies

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

  • Full project title: Stem cells for biological assays of novel drugs and predictive toxicology
  • Start date: 1st October 2012
  • Duration: 5 years
  • Total cost: € 55.6 million
  • Project coordinator: F. Hoffmann-La Roche Ltd
  • Managing entity: University of Oxford

 

The Stem Cell Unit, Department of Genetics

Edmond J. Safra Campus, Givat Ram

Jerusalem 91904, Israel

 

huji.ac.il

benvenisty.huji.ac.il/

 

Project leader

 
Prof. Nissim Benvenisty
 
E-Mail  

Project staff

 
Dr. Ofra Yanuka
 
E-Mail  

Institute presentation

The Hebrew University of Jerusalem, Israel’s first university, is a multidisciplinary institution of higher learning and research, where intellectual pioneering, cutting-edge scientific discovery, and a passion for learning flourish. Research and creativity have always been the cornerstone of the Hebrew University of Jerusalem since its inception in 1928.  For over 80 years, Hebrew University researchers have not only carried out outstanding basic research, but have also responded to the needs of society. The University is justly proud of its position at the cutting edge of world science. Its researchers publish widely in leading international scientific and scholarly journals, conduct collaborative research projects with noted scholars from other countries and compete successfully for research grants from international and national funding sources (ERC, FP7, NIH, DFG, Human Frontier, Howard Hughes, ISF).The Hebrew University of Jerusalem has been ranked among the top universities in the world in two comprehensive surveys conducted by The Times Higher Education Supplement of London and Shanghai University. Funding of more than $150 million supports 2,700 research projects in progress. Within the framework of these projects, 45% of all the student body (23,000) are graduate students and are working towards advanced degrees, gaining invaluable experience as the project leaders of tomorrow. The University has educated and trained thousands of students - 28% of all doctoral candidates in Israel are enrolled at the Hebrew University- providing the skilled manpower needed for many aspects of Israel's development.

 

Department of Physiology, Anatomy and Genetics, Oxford University

South Parks Road

OX1 3PT Oxford

 

mrcfgu.ox.ac.uk

 

As of 1st July 2013 the MRC Functional Genomics Unit was established as a

University Unit at the University of Oxford and thus the MRC formally terminated

its participation in StemBANCC.


Institute presentation

The Functional Genomics Unit (FGU) uses genomic information to determine mechanisms of disease and to develop novel therapeutic approaches. We focus our research on common neurological diseases (e.g. motor neuron disease, Parkinson’s disease or Alzheimer’s disease) treating each of them as a family of disorders whose members occur only rarely in the general population. Developing treatments for such disorders requires an understanding of the common biochemical pathways which lead to malfunction and the development of a family of products for their treatment.

In the Unit we combine the power of computational analyses and the latest experimental technologies in model organisms to reveal the roles of genes and genomes in health and disease.  The Unit pursues the translation of these discoveries into improved healthcare products and patient treatments via partnerships with clinicians as well as the Pharmaceutical and Biotechnology Industries.

 

Avenue Pierre Brossolette, 1

91385, Chilly-Mazarin

FRANCE

 

sanofi.com

 

Project leader

 
Dr. Cecile Orsini
 
Phone +33 1 58 93 31 30
E-Mail  

Project staff

 
Dr. Andreas Czich
 
Phone +49 69 305 20710
E-Mail  

 

 
Dr. Jean-Michel Guillon
 
Phone +33 1 58 93 85 59
E-Mail  

 

 
Dr. Gilles Labbe
 
Phone +33 1 58 93 35 27
E-Mail  

 

 
Dr. Jean-Pierre Martinolle
 
Phone +33 4 99 77 60 49
E-Mail  

 

 
Dr. Marie-Christine Multon
 
Phone +33 1 58 93 34 770
E-Mail  

 

 
Dr. Michel Partiseti
 
Phone +33 1 58 93 29 96
E-Mail  

 

 
Dr. Emmanuel Spanakis
 
Phone +33 1 58 93 34 35
E-Mail  

 

 
Laurence Mazuranok
 
Phone +33 426 23 23 80
E-Mail  

 


Institute presentation

Within the SANOFI pharmaceutical group, Sanofi-Aventis Recherche & Developpement (SARD) focuses on finding innovative solutions to major public health challenges and to patients’ needs.
The group concentrates its efforts on several major priorities including diabetes, oncology, ophthalmology, infectious diseases, aging, neurodegenerative diseases, immuno-inflammation, fibrosis and tissue repair. Sanofi-Aventis Recherche & Developpement (SARD) through three departments (Global Biotherapeutics, DSAR: Disposition, Safety & Animal Research and LGCR: Lead Generation to Candidate Realization) is involved in StemBANCC in 7 work-packages out of 12.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline